Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDA) remains among the most challenging malignancies to treat. At diagnosis, the tumor often already extends beyond the confines of the pancreas, spreading to an extent such that primary surgery with curative intent is very rarely feasible. Considerable momentum is now being given to a treatment strategy involving neoadjuvant chemotherapy or chemotherapy and radiation therapy in patients with nonmetastatic PDA. The main advantage of this strategy is better selection of patients likely to benefit from curative-intent surgery through the achievement of negative resection margins. Patients with rapidly progressive disease are identified and are spared ineffective surgery with its attendant morbidity. Neoadjuvant therapy can downstage tumors classified as locally advanced at initial imaging studies to resectable tumors. However, the imaging study evaluation of the response to neoadjuvant therapy is extremely complex. Thus, the diagnostic performance of imaging studies is not sufficient to ensure the accurate selection of patients in whom negative-margin resection is likely to be achieved. More specifically, standard criteria for predicting vascular invasion, based on the amount of tumor-vessel contact, are not valid after neoadjuvant therapy. ©RSNA, 2018
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Isoattenuating Pancreatic Adenocarcinoma at Multi–Detector Row CT: Secondary Signs
Prokesch, R. W., Chow, L. C., Beaulieu, C. F., Bammer, R., & Jeffrey, R. B. (2002) · Radiology · doi:10.1148/radiol.2243011284 · Cited by 337
Kauhanen, S. P., Komar, G., Seppänen, M. P., Dean, K. I., Minn, H. R., Kajander, S. A., Rinta-Kiikka, I., Alanen, K., Borra, R. J., Puolakkainen, P. A., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b2fafa · Cited by 317
Yoon, S. H., Lee, J. M., Cho, J. Y., Lee, K. B., Kim, J. E., Moon, S. K., Kim, S. J., Baek, J. H., Kim, S. H., Kim, S. H., et al. (2011) · Radiology · doi:10.1148/radiol.11101133 · Cited by 257
Ishigami, K., Yoshimitsu, K., Irie, H., Tajima, T., Asayama, Y., Nishie, A., Hirakawa, M., Ushijima, Y., Okamoto, D., Nagata, S., et al. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2007.09.012 · Cited by 79
Cited by
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O’Reilly, E. M., Hackert, T., Golan, T., Prager, G., Haustermans, K., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.009 · Cited by 610
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review
Elbanna, K. Y., Jang, H.-J., & Kim, T. K. (2020) · Insights into Imaging · doi:10.1186/s13244-020-00861-y · Cited by 162
“This category is variable among different institutions particularly in defining the criteria related to venous invasion due to variations in vascular reconstruction surgeries [40].”
BackgroundFactors associated with missed and misinterpreted cases of pancreatic ductal adenocarcinoma
Kang, J. D., Clarke, S. E., & Costa, A. F. (2021) · European Radiology · doi:10.1007/s00330-020-07307-5 · Cited by 84
Advancements in standardizing radiological reports: a comprehensive review
Pesapane, F., Tantrige, P., De Marco, P., Carriero, S., Zugni, F., Nicosia, L., Bozzini, A. C., Rotili, A., Latronico, A., Abbate, F., et al. (2023) · Medicina · doi:10.3390/medicina59091679 · Cited by 50
Metadata
- Authors
- Zins, M., Matos, C., & Cassinotto, C.
- Venue
- Radiology
- Published
- 2018-05
- Volume
- 287
- Issue
- 2
- Pages
- 374-390
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2800693655
- Cited by
- 187
- References
- 9
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.